Simultaneous control of third-degree graft-versus-host disease and prevention of recurrence of juvenile myelomonocytic leukemia (JMML) with 6-mercaptopurine following fulminant JMML relapse early after KIR mismatched bone marrow transplantation

Journal of Pediatric Hematology/Oncology

Volumn 27, Issue 12, 2005, Pages 672-674

  Stachel, Daniel K ^a   Leipold, Alfred ^a   Kuhlen, Michaela ^a   Gravou Apostolatou, Chara ^a   Hirv, Kaimo ^b   Bader, Peter ^c   Niemeyer, Charlotte M ^d   Beck, Jörn D ^a   Holter, Wolfgang ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b German Red Cross Blood Transfusion Service Baden Württemberg Hessen and University Hospital Ulm   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

6 mercaptopurine; Graft versus host disease; Graft versus leukemia; Juvenile myelomonocytic leukemia; Relapse after bone marrow transplant

Indexed keywords

BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; KILLER IMMUNOGLOBULIN LIKE RECEPTOR; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RECEPTOR; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CASE REPORT; CHIMERA; CLINICAL FEATURE; CORTICOSTEROID THERAPY; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JUVENILE MYELOMONOCYTIC LEUKEMIA; LEUKEMIA REMISSION; MALE; MEDICAL EXAMINATION; PRESCHOOL CHILD; PRIORITY JOURNAL; TREATMENT OUTCOME;

6-MERCAPTOPURINE; ANTIMETABOLITES, ANTINEOPLASTIC; BUSULFAN; CYCLOPHOSPHAMIDE; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HLA-B ANTIGENS; HLA-C ANTIGENS; HUMANS; INFANT; LEUKEMIA, MYELOMONOCYTIC, ACUTE; MALE; MELPHALAN; RECEPTORS, IMMUNOLOGIC; RECURRENCE; REMISSION INDUCTION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 29144531833     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/01.mph.0000193471.91690.f4     Document Type: Article

References (14)

1. Niemeyer CM, Arico M, Basso G, et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Blood. 1997;89:3534-3543.
2. Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999;94:333-339.
3. Ruggeri L, Capanni M, Mancusi A, et al. Alloreactive natural killer cells in mismatched hematopoietic stem cell transplantation. Blood Cells Mol Dis. 2004;33:216-221.
4. Hsu KC, Keever-Taylor CA, Wilton A, et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood. 2005;105:4878-4884.
5. Bader P, Holle W, Klingebiel T, et al. Quantitative assessment of mixed hematopoietic chimerism by polymerase chain reaction after allogeneic BMT. Anticancer Res. 1996;16:1759-1763.
6. Kreyenberg H, Holle W, Mohrle S, et al. Quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection: the Tuebingen experience. Leukemia. 2003;17:237-240.
7. Lutz P, Zix-Kieffer I, Souillet G, et al. Juvenile myelomonocytic leukemia: analyses of treatment results in the EORTC Children's Leukemia Cooperative Group (CLCG). Bone Marrow Transplant. 1996;18:1111-1116.
8. Locatelli F, Niemeyer C, Angelucci E, et al. Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on Myelodysplastic Syndrome in Childhood. J Clin Oncol. 1997;15:566-573.
9. Smith FO, King R, Nelson G, et al. Unrelated donor bone marrow transplantation for children with juvenile myelomonocytic leukaemia. Br J Haematol. 2002;116:716-724.
10. Orchard PJ, Miller JS, McGlennen R, et al. Graft-versus-leukemia is sufficient to induce remission in juvenile myelomonocytic leukemia. Bone Marrow Transplant. 1998;22:201-203.
11. Worth A, Rao K, Webb D, et al. Successful treatment of juvenile myelomonocytic leukemia relapsing after stem cell transplantation using donor lymphocyte infusion. Blood. 2003;101:1713-1714.
12. Yoshimi A, Bader P, Matthes-Martin S, et al. Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia. Leukemia. 2005;19:971-977.
13. Neudorf S, Nourani A, Kempert P, et al. Chemotherapy and donor leukocyte infusions for relapsed juvenile myelomonocytic leukemia (JMML). Bone Marrow Transplant. 2004;33:1069.
14. Ruggeri L, Mancusi A, Capanni M, et al. Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer. Curr Opin Immunol. 2005;17:211-217.